France

AB Science SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS)

Lead Product(s): Masitinib,Riluzole

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

Study AB19001 is an international Phase 3 study to compare the efficacy and safety of masitinib in combination with riluzole vs placebo in combination with riluzole in ALS.

MedDay Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

MedDay Reports Top-Line Data from Phase III Trial “SPI2”

Lead Product(s): Biotin

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

SPI2 was designed to confirm the results of the first positive Phase III study, MS-SPI, in progressive multiple sclerosis (MS).

AB Science SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis

Lead Product(s): Masitinib

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2020

Details:

Masitinib significantly delays disability progression on EDSS in patients with primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

AB Science SA

AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS)

MedDay Pharmaceuticals

MedDay Reports Top-Line Data from Phase III Trial “SPI2”

AB Science SA

AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis